(Total Views: 462)
Posted On: 04/07/2020 11:01:41 AM
Post# of 154212
I did say quick and limited analysis. I simply used the numbers from Yahoo finance.
Changing subjects, I think the large size of float is a lot of friction the SP needs to overcome to move significantly higher. Need some news (like lero IS the drug to keep everyone off ventilators thereby saving lives!) to create enough pressure for SP to break out.
Far into the future (6-9 months? after FDA approval?), this Company needs to get a good chunk of the float into the hands of institutional investors, which it can't do without the SP being >$5 plus some other regulatory paperwork. The other route is to do a reverse split, which I wouldn't be opposed to (if I were a long term investor) since there is some potentially great product here.
But I digress. My point was to give my 2 cents about why its so hard for the SP to rise with what we know about lero and treating the COVID-19 symptom that is killing people.
Changing subjects, I think the large size of float is a lot of friction the SP needs to overcome to move significantly higher. Need some news (like lero IS the drug to keep everyone off ventilators thereby saving lives!) to create enough pressure for SP to break out.
Far into the future (6-9 months? after FDA approval?), this Company needs to get a good chunk of the float into the hands of institutional investors, which it can't do without the SP being >$5 plus some other regulatory paperwork. The other route is to do a reverse split, which I wouldn't be opposed to (if I were a long term investor) since there is some potentially great product here.
But I digress. My point was to give my 2 cents about why its so hard for the SP to rise with what we know about lero and treating the COVID-19 symptom that is killing people.
(0)
(0)
